Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Down 19.5% in April

Dare Bioscience, Inc. (NASDAQ:DARE) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totaling 170,167 shares, a decrease of 19.5% from the March 31st total of 211,491 shares. Based on an average trading volume of 66,992 shares, the short-interest ratio is presently 2.5 days. Approximately 1.2% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dare Bioscience in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Dare Bioscience Stock Performance

Shares of DARE traded up $0.17 during mid-day trading on Thursday, hitting $2.27. The company’s stock had a trading volume of 236,390 shares, compared to its average volume of 288,483. Dare Bioscience has a one year low of $1.27 and a one year high of $9.19. The firm has a market capitalization of $33.05 million, a PE ratio of -1.82 and a beta of 0.90. The stock’s 50-day moving average is $1.77 and its two-hundred day moving average is $1.87.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Thursday, March 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.42. The company had revenue of $1.02 million for the quarter, compared to the consensus estimate of $0.75 million. Analysts expect that Dare Bioscience will post -1.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. LPL Financial LLC acquired a new position in shares of Dare Bioscience during the fourth quarter valued at about $28,000. Raymond James Financial Inc. lifted its stake in shares of Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 13,650 shares during the period. Virtu Financial LLC acquired a new stake in Dare Bioscience during the third quarter worth about $37,000. Finally, AMH Equity Ltd grew its position in Dare Bioscience by 20.0% during the third quarter. AMH Equity Ltd now owns 232,373 shares of the biotechnology company’s stock worth $488,000 after buying an additional 38,770 shares in the last quarter. Institutional investors own 6.70% of the company’s stock.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.